Major combined electrolyte deficiency during therapy with low-dose Cisplatin, 5-Fluorouracil and Interferon alpha: Report on several cases and review of the literature [ISRCTN62866759]

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Hoffmann, Katrin ^a   Marten, Angela ^a   Lindel, Katja ^a   Fritz, Stefan ^a   Jager, Dirk ^a   Buchler, Markus W ^a   Schmidt, Jan ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CALCIUM; CISPLATIN; FLUOROURACIL; GLUCONATE CALCIUM;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; ELECTROLYTE DISTURBANCE; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; HYPOCALCEMIA; IMMUNOTHERAPY; INCIDENCE; INTENSIVE CARE; LOW DRUG DOSE; MALE; MEDICAL SPECIALIST; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; RANDOMIZED CONTROLLED TRIAL;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCIUM; CISPLATIN; COMBINED MODALITY THERAPY; FLUOROURACIL; HUMANS; HYPOCALCEMIA; INTERFERON-ALPHA; MAGNESIUM; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; WATER-ELECTROLYTE BALANCE;

EID: 33744922978     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-128     Document Type: Article

References (21)

1. Arany I, Safirstein RL: Cisplatin Nephrotoxocity. Seminars in Nephrology 2003, 23:460-464.
2. Fillastre JP, Raguenez-Viotte G: Cisplatin nephrotoxicity. Toxicol Lett 1989, 46:163-175.
3. Cornelson TL, Reed E: Nephrotoxicity and hydration management for Cisplatin, Carboplatin und Ormaplatin. Gynecologic Oncology 1993, 50:147-158.
4. Goren MP: Cisplatin Nephrotoxicity affects Magnesium and Calcium Metabolism. Medical and Pediatric Oncology 2003, 41:186-189.
5. Weiss-Guillet EM, Takala J, Jakob SM: Diagnosis and management of electrolyte emergencies. Best Practise, Research Clinical Endocrinology and Metabolism 2003, 17:623-651.
6. Pattou F, Combemale F, Fabre S, Carnaille B, Decloux M, Wemenau JL, Racadot A, Proye C: Hypocalcaemia following thyroid surgery: incidence and prediction of the outcome. World Journal of Surgery 1998, 22:718-724.
7. Prough DS: Physiologic acid-base and electrolyte changes in acute and chronic renal failure patients. Anesthesiol Clin North America 2000, 18:809-833.
8. Hadjis T, Grieff M, Lockhat D, Kaye M: Calcium metabolism in acute renal failure due to rhabdomyolysis. Clin Nephrol 1993, 39:22-27.
9. Pitchumoni CS, Agarwal N, Jain NK: Systemic complications of acute pancreatitis. Am J Gastroenterol 1988, 83:597-606.
10. Bazarbashi S, Rahal M, Raja MA, Weshi AE, Pai C, Ezzat A, Hanash K: A Pilot Trial of Combination Cisplatin, 5-Fluorouracil and Interferon-alpha in the Treatment of Advanced Oesophageal Carcinoma. Chemotherapy 2002, 48:211-216.
11. Picozzi VJ, Traverso LW: The Virginia Mason approach to localized pancreatic cancer. Surg Oncol Clin N Am 2004:663-674.
12. Bazarbashi S, Pai C, Raja MA, Rahal M, Ezzat A, Hanash K: Phase II Trial of cisplatin, 5-fluorouracil, and interferon-alpha.2B as first line treatment of advanced urothelial cancer. Urologic Oncology 2003, 21:185-189.
13. Vokes EE, Ratain MJ, Mick R, McEvilly JM, Haraf D, Kozloff M, Hamasaki V, Weichselbaum RR, Panje RR, Wenig B: Cisplatin, Fluorouracil, and Leucovorin augmented by Interferon Alfa-2b in Head and Neck Cancer: A Clinical and Pharmacologic Analysis. Journal of Clinical Oncology 1993, 11:360-368.
14. Knaebel HP, Maerten A, Schmidt J, Hoffmann K, Seiler C, Lindel K, Schmitz-Winnenthal HF, Fritz S, Hermann T, Goldschmidt H, Mansmann U, Debus J, Diehl V, Buchler MW: Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic carcinoma - CapRI: study protocoll (ISRCTN62866759). BMC Cancer 2005:5.
15. Picozzi VJ, Kozarek RA, Traverso LW: Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. American Journal of Surgery 2003, 185:476-480.
16. Dai LJ, Ritchie G, Kerstan D, Kang HS, Cole DE, Quamme GA: Magnesium transport in the renal distal convoluted tubule. Physiol Rev 2001, 81:51-84.
17. Yasumasu T, Ueda T, Uozumi J, Mihara Y, Kumazawa J: Comparative study of cisplatin and carboplatin on pharmacokinetics, nephrotoxicity and effect on renal nuclear DNA synthesis in rats. Pharmacol Toxicol 1992, 70:143-147.
18. Hayes FA, Green AA, Senzer N, Pratt CB: Tetany: A Complication of Cis-Dichlorodiammineplatinum(II) Therapy. Cancer Treatment Reports 1979, 63:547-548.
19. Jones GJ, Itri LM: Safety and Tolerance of Recombinant Interferon Alfa-2b (Roferon-A) in Cancer Patients. Cancer 1986, 57:1709-1715.
20. Wanebo HJ, Glicksman AS, Vezeridis MP, Clark J, Tibbetts L, Koness RJ, Levy A: Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer. Arch Surg 2000, 135:81-87.
21. Moutardier V, Turrini O, Huiart L, Viret F, Giovannini MH, Magnin V, Lelong B, Bories E, Guiramand J, Sannini A, Giovannini M, Houvenaeghel C, Blache JL, Moutradier JC, Delpero JR: A reappraisal of preoperative chemoradiation for localized pancreatic head ductal adenocarcinoma in a 5-year single-institution experience. J Gastrointest Surg 2004, 8:502-510.